布地奈德对咳嗽变异性哮喘诱导痰炎症介质的影响及其临床意义探讨
The effect of Budesonide on inflammatory factors in induced sputum in patients with cough variant asthma and its clinical significancy

李影.布地奈德对咳嗽变异性哮喘诱导痰炎症介质的影响及其临床意义探讨[J].内科急危重症杂志,2015,21(1):

扫码阅读全文

DOI：

英文关键词:Budesonide cough variant asthma(CVA) inflammatory factors

基金项目:

作者	单位	E-mail
李影	枣庄市王开传染病医院内三科	linlin197810@163.com

摘要点击次数: 3407

全文下载次数: 4306

中文摘要:

目的观察布地奈德粉吸入剂使用后咳嗽变异性哮喘患者诱导痰中炎症介质的动态变化,并探讨其临床意义。方法选取2011年2月~2013年6月山东省枣庄市王开传染病医院初次确诊进行治疗的CVA患者84例,另取我院体检中心健康志愿者40例作为正常对照。对照组和CVA组治疗前、治疗后2个月、治疗后4个月、治疗后8个月、随访4个月后行诱导痰操作,ELISA法检测诱导痰IL-6表达,细胞沉渣涂片检测嗜酸性粒细胞(EOS)比例。结果CVA患者诱导痰IL-6表达水平为76.5±12.4 μg/ml,EOS比例为14.7±4.2%,均显著高于健康对照的17.4±3.2 μg/ml和2.3±0.6%(P<0.01)。CVA患者治疗前、治疗后2个月、治疗后4个月、治疗后8个月、随访4个月后,各组之间IL-6表达水平和EOS比例存在显著性差异(P<0.05)。布地奈德治疗临床治疗有效率为95.2%,复发率为9.5%。CVA复发患者诱导痰IL-6表达水平为62.9±11.3 μg/ml,EOS比例为10.4±2.9%,均显著高于非复发患者的28.3±4.4μg/ml和5.8±1.4%(P<0.01)。结论布地奈德气雾剂可以抑制CVA诱导痰炎症介质的表达,长期用药更有利于布地奈德抗炎作用的发挥。

英文摘要:

Objective To observe the effect of Budesonide on inflammatory factors in induced sputum in patients with cough variant asthma(CVA) and explore its clinical significancy. Methods 84 CVA patients were sellected in this study. Another 40 healthy person were sellected as control. The expression of IL-6 in induced sputum was detected by ELISA analysis. The percent of EOS cells were determined by microscope detection. Results The IL-6 expression induced sputum of CVA patients was 76.5±12.4 μg/ml, and the percent of EOS cells was 14.7±4.2%, which was significant higher than that of 17.4±3.2 μg/ml and 2.3±0.6% in control group (P <0.01). There was significant difference of IL-6 expression and EOS cells percent among pre-treatment, post-treatment for 2 monthes, post-treatment for 4 monthes, post-treatment for 8 monthes, and followed up for 4 monthes(P <0.05). The clinic effective rate was 95.2%, and the recurrence rate was 9.5%. The IL-6 expression induced sputum of recurrence patients was 62.9±11.3 μg/ml, and the percent of EOS cells was 10.4±2.9%, which was significant higher than that of 28.3±4.4 μg/ml and 5.8±1.4% in non- recurrence patients (P <0.01). Conclusion Budesonide can reduce the inflammatory reaction in CVA patients, and longer treatmen was contribute to its anti-inflammatory function.